Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Mitigation of climate change requires that new routes for the production of fuels and chemicals be as oil-independent as possible. The microbial conversion of lignocellulosic feedstocks into terpene-based biofuels and bioproducts represents one such route. This work builds upon previous demonstrations that the single-celled carotenogenic basidiomycete, Rhodosporidium toruloides, is a promising host for the production of terpenes from lignocellulosic hydrolysates.

Results: This study focuses on the optimization of production of the monoterpene 1,8-cineole and the sesquiterpene α-bisabolene in R. toruloides. The α-bisabolene titer attained in R. toruloides was found to be proportional to the copy number of the bisabolene synthase (BIS) expression cassette, which in turn influenced the expression level of several native mevalonate pathway genes. The addition of more copies of BIS under a stronger promoter resulted in production of α-bisabolene at 2.2 g/L from lignocellulosic hydrolysate in a 2-L fermenter. Production of 1,8-cineole was found to be limited by availability of the precursor geranylgeranyl pyrophosphate (GPP) and expression of an appropriate GPP synthase increased the monoterpene titer fourfold to 143 mg/L at bench scale. Targeted mevalonate pathway metabolite analysis suggested that 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGR), mevalonate kinase (MK) and phosphomevalonate kinase (PMK) may be pathway bottlenecks are were therefore selected as targets for overexpression. Expression of HMGR, MK, and PMK orthologs and growth in an optimized lignocellulosic hydrolysate medium increased the 1,8-cineole titer an additional tenfold to 1.4 g/L. Expression of the same mevalonate pathway genes did not have as large an impact on α-bisabolene production, although the final titer was higher at 2.6 g/L. Furthermore, mevalonate pathway intermediates accumulated in the mevalonate-engineered strains, suggesting room for further improvement.

Conclusions: This work brings R. toruloides closer to being able to make industrially relevant quantities of terpene from lignocellulosic biomass.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8058980PMC
http://dx.doi.org/10.1186/s13068-021-01950-wDOI Listing

Publication Analysis

Top Keywords

mevalonate pathway
16
production terpenes
8
terpenes lignocellulosic
8
lignocellulosic biomass
8
pathway genes
8
lignocellulosic hydrolysate
8
production
7
lignocellulosic
6
expression
5
mevalonate
5

Similar Publications

Engineered microbial production of carotenoids and their cleavage products: Recent advances and prospects.

Biotechnol Adv

September 2025

Science Center for Future Foods, Jiangnan University, 1800 Lihu Road, Wuxi 214122, China; Key Laboratory of Industrial Biotechnology, Ministry of Education, School of Biotechnology, Jiangnan University, 1800 Lihu Road, Wuxi 214122, China; Jiangsu Province Basic Research Center for Synthetic Biology,

Carotenoids and their cleavage products (referred to as apocarotenoids) have functional properties such as antioxidant activity, fragrance, and color that are important in the pharmaceutical, healthcare, cosmetics, and food industries. Currently, carotenoids and apocarotenoids are primarily obtained through extraction from natural sources or chemical synthesis, both of which are associated with inefficiencies, environmental impact, and product limitations. Ongoing advances in metabolic engineering and synthetic biology have positioned heterologous biosynthesis as a promising, efficient, and sustainable production strategy.

View Article and Find Full Text PDF

Mevalonate Metabolic Reprogramming Drives Cisplatin Resistance in Bladder Cancer: Mechanisms and Therapeutic Targeting.

Protein Pept Lett

September 2025

Department of Urology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou730000, Gansu, China.

Introduction: Dysregulation of mevalonate metabolism is a hallmark of tumorigenesis and therapy resistance across malignancies, though its role in bladder cancer remains unclear. This study aimed to elucidate its impact on prognosis and cisplatin chemosensitivity in bladder cancer.

Methods: Transcriptomic data and clinical information of bladder cancer patients were obtained from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) databases.

View Article and Find Full Text PDF

Activity-based probes and chemical proteomics uncover the biological impact of targeting HMGCS1 in the mevalonate pathway.

J Biol Chem

September 2025

Chemical Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Pharmacology, Weill Cornell Graduate School of Medical Sciences, New York, NY, USA. Electronic address:

Mevalonate is a precursor for essential metabolites, such as isoprenoids and sterols. Its synthesis starts with HMGCS1 producing HMG-CoA, which is then converted to mevalonate by HMGCR, a target of statins. Cancer cells often upregulate enzymes in the mevalonate pathway (MVP) to meet their metabolic demands, leading to the development of inhibitors targeting several enzymes in this pathway.

View Article and Find Full Text PDF

In Vitro synergy of Farnesyltransferase inhibitors in combination with colistin against ESKAPE bacteria.

PLoS One

September 2025

Faculty of Health, Institute of Pharmacology and Toxicology, Centre for Biomedical Education and Research (ZBAF), School of Medicine, Witten/Herdecke University, Witten, Germany.

The emergence of antibiotic resistance continues to pose a significant global challenge. Drug repurposing, wherein existing therapeutics are evaluated for new applications, offers a promising strategy to address this issue. Farnesyltransferase inhibitors (FTIs), initially developed for cancer therapy, have demonstrated antimicrobial activity against several gram-positive bacteria.

View Article and Find Full Text PDF

Cardiovascular disease remains a major global health challenge, with dyslipidaemia being a key modifiable risk factor. While low density lipoprotein cholesterol (LDL-C) is the primary target for lipid-lowering therapies, recent evidence highlights the importance of triglycerides, apolipoprotein B (apoB), and lipoprotein(a) [Lp(a)] for residual cardiovascular risk. Current lipid-lowering therapies target key enzymes and proteins involved in cholesterol and lipid metabolism.

View Article and Find Full Text PDF